Antigen arrays for treatment of bone disease

Details Antigen arrays for treatment of bone disease Antigen arrays for treatment of bone disease

2006-10-31

2006-10-31

Mosher, Mary E. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S193100, C424S194100, C424S195110, C424S400000, C530S403000, C530S404000

Reexamination Certificate

active

07128911

ABSTRACT:
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular a RANKL protein, RANKL fragment or RANKL peptide-VLP-array. More specifically, the invention provides a composition comprising a virus-like particle and at least one RANKL protein, RANKL fragment or RANKL peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of bone diseases and as a pharmaccine to prevent or cure bone diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5843678 (1998-12-01), Boyle
patent: 5935821 (1999-08-01), Chatterjee et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6242213 (2001-06-01), Anderson
patent: 6242586 (2001-06-01), Gorman et al.
patent: 6380364 (2002-04-01), Mueller et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 2004/0033211 (2004-02-01), Bachmann et al.
patent: 2004/0059094 (2004-03-01), Bachmann et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0076645 (2004-04-01), Bachmann et al.
patent: 2004/0141984 (2004-07-01), Bachmann et al.
patent: 0 259 149 (1993-12-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 421 635 (1995-07-01), None
patent: 0 677 111 (1997-05-01), None
patent: 2000-102390 (2000-04-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 92/13081 (1992-08-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 98/46751 (1998-10-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 99/29865 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 00/15807 (2000-03-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 01/77158 (2001-10-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 02/14478 (2002-02-01), None
patent: WO 2005/117963 (2005-12-01), None
patent: WO 2005/117983 (2005-12-01), None
Hertz et al. Journal of Bone and Mineral Research Suppl. 1, p. S222, abstract F422, Sep. 2001.
Abraham, J.M., et al., “An invertible element of DNA controls phase variation of type 1 fimbriae ofEscherichia coli,”Proc. Natl. Acad. Sci. USA 82:5724-5727, National Academy Press (1985).
Abraham, S.N., et al., “Glycerol-Induced Unraveling of the Tight Helical Conformation ofEscherichia coliType 1 Fimbriae,”J. Bacteriol. 174:5145-5148, American Society for Microbiology (1992).
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,”Virology 170:238-242, Academic Press, Inc. (1989).
Aguzzi, A., “Prion diseases, blood and the immune system: concerns and reality,”Haematologica 85:3-10, Il Pensiero Scientifico Editore (Jan. 2000).
Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Cheomkine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,”J. Exp. Med. 190:1123-1134, The Rockefeller University Press (1999).
Ansel, K.M., et al., “A chemokine-driven positive feedback loop organizes lymphoid follicles,”Nature 406:309-314, Nature Publishing Group (Jul. 2000).
Antonysamy, M.A., et al., “Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the Functional Differentiation of Dendritic Cell Progenitors,”J. Immunol. 162:577-584, The American Association of Immunologists (1999).
Arenberg, D.A., et al., “The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model,”Cancer Immunol. Immunother. 49:587-592, Springer-Verlag (Jan. 2001).
Arnon, R., et al., “A mimotope peptide-based vaccine againstSchistosoma mansoni: synthesis and characterization,”Immunology 101:555-562, Blackwell Science, Ltd. (Dec. 2000).
Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17:553-558, Elsevier Science, Ltd. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation,”J. Exp. Med. 189:1025-1031, The Rockefeller University Press (1999).
Banerjee, R.R., and Lazar, M.A., “Dimerization of Resistin and Resistin-like Molecules Is Determined by a Single Cysteine,”J. Biol. Chem. 276:25970-25973, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2001).
Bard, F. et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,”Nat. Med. 6:916-919, Nature Publishing Company (Aug. 2000).
Bass, S., and Yang, M., “Expressing cloned genes inEscherichia coli,” inProtein Function: A Practical Approach, 2nd ed., Creighton, T.E., ed., IRL Press, Oxford, Great Britain, pp. 29-55 (1997).
Bernhagen, J., et al., “Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF),”Biochemistry 33:14144-14155, American Chemical Society (1994).
Biaselle, C.J., and Millar, D.B., “Studies on Triton X-100 detergent micelles,”Biophys. Chem. 3:355-361, North-Holland Publushing Company (1975).
Bleul, C.C., et al., “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,”Nature 382:829-833, Nature Publishing Group (1996).
Blomfield, I.C., et al., “Type 1 Fimbriation andfimEMutants ofEscherichia coliK-12,”J. Bacteriol. 173:5298-5307, American Society for Microbiology (1991).
Blomfield, I.C., et al., “Integration host factor stimulates both FimB- and FimE- mediated site-specific DNA inversion that controls phase variation of type 1 fimbriae expression inEscherichia coli,” Mol. Microbiol. 23:705-717, Blackwell Science, Ltd. (1997).
Boder, E.T., and Wittrup, K.D., “Yeast Surface Display for Directed Evolution of Protein Expression, Affinity, and Stability,”Methods Enzymol. 328:430-444, Academic Press (Oct. 2000).
Adams, S.E., et al., “The expression of hybrid HIV:Ty virus-like particles in yeast,”Nature 329:68-70, Macmillan Publishers Ltd (1987).
Anderson, D.M., et al., “A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function,”Nature 390(6656):175-179, Macmillan Publishers Ltd. (1997).
Bachmann, M.F., et al., “Dendritic cells proces

Affiliated with

Also associated with

Rating

Antigen arrays for treatment of bone disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antigen arrays for treatment of bone disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigen arrays for treatment of bone disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3717522